Product nameCabergoline, D2-like receptor agonist
DescriptionD2-like receptor agonist
Storage instructionsStore at +4°C. The product can be stored for up to 12 months.
Solubility overviewSoluble in ethanol to 100 mM and in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120564 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
PC12 cells were incubated at 37ºC for 30 minutes with vehicle control (0 µM) and different concentrations of cabergoline (ab120564). Increased expression of AKT1 (phospho S473) (ab66138) in PC12 cells correlates with an increase in cabergoline concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab66138 at 1/1000 dilution and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
This product has been referenced in:
- Chiba S et al. Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology (Berl) 211:291-301 (2010). Read more (PubMed: 20526584) »
- Kvernmo T et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065-78 (2006). Read more (PubMed: 16982285) »
- Eguchi K et al. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr J 42:153-61 (1995). Read more (PubMed: 7627259) »